- Report
- April 2023
- 122 Pages
Global
From €3500EUR$4,255USD£3,158GBP
- Report
- April 2023
- 125 Pages
Global
From €3500EUR$4,255USD£3,158GBP
- Report
- February 2024
- 114 Pages
Global
From €3500EUR$4,255USD£3,158GBP
- Report
- February 2024
- 96 Pages
Global
From €3500EUR$4,255USD£3,158GBP
- Report
- June 2022
- 86 Pages
Global
From €3500EUR$4,255USD£3,158GBP
- Report
- October 2023
- 80 Pages
Russia
From €661EUR$750USD£576GBP
€1322EUR$1,500USD£1,152GBP
- Report
- October 2023
- 80 Pages
Poland
From €661EUR$750USD£576GBP
€1322EUR$1,500USD£1,152GBP
- Report
- March 2023
- 100 Pages
Africa
From €881EUR$1,000USD£768GBP
€1762EUR$2,000USD£1,536GBP
- Report
- September 2025
Europe
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP
- Report
- September 2025
Global
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP
- Report
- September 2025
North America
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP
- Report
- September 2025
Europe
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP
- Report
- September 2025
- 20 Pages
Europe
From €1674EUR$1,900USD£1,459GBP
- Report
- September 2025
Europe
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP
- Report
- September 2025
Europe
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP
- Report
- September 2025
China
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP
- Report
- September 2025
United States
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP
- Report
- September 2025
United Kingdom
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP
- Report
- September 2025
North America
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP
- Report
- September 2025
Europe
From €1846EUR$2,095USD£1,609GBP
€3516EUR$3,990USD£3,065GBP

The Gastrointestinal Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat diseases and disorders of the gastrointestinal tract. These drugs are used to treat conditions such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, and gastroesophageal reflux disease. Commonly prescribed drugs include antacids, proton pump inhibitors, and H2 receptor antagonists.
The Gastrointestinal Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck & Co., AstraZeneca, and Novartis. These companies are constantly developing new drugs and treatments to meet the needs of patients. Show Less Read more